Preclinical immunogenicity and efficacy of a multiple antigen-presenting system (mapstm) sars-cov-2 vaccine

HIGHLIGHTS

  • who: Brian Cieslewicz and colleagues from the Division of Infectious Diseases, Department of Medicine, Boston Children`s Hospital, Boston, MA, USA have published the research: Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine, in the Journal: Vaccines 2022, 1069 of /2022/
  • what: This work demonstrated that T_cell generated by MAPS is correlated with secretion of proinflammatory cytokines environment (TNF-u03b1, IL-12, IL-23, and IL-1u03b2) and depends on TLR2 activation, in a dose-dependent manner . The authors show here that the SARS-CoV-2 MAPS vaccine . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?